Carmen Moreno
Autonomous University of Barcelona
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carmen Moreno.
Clinical Infectious Diseases | 1997
Francesca March; Xavier Garriga; Purificación Rodríguez; Carmen Moreno; Montserrat Garrigó; Pere Coll; Guillem Prats
We describe five compliant patients with human immunodeficiency virus (HIV)-associated tuberculosis (TB) that relapsed, with acquisition of resistance by the original Mycobacterium tuberculosis strains. Both the first and second isolates from each patient had the same IS (insertion sequence) 6110-based DNA fingerprint patterns. Three of the five patients developed TB that was resistant to rifampin alone; no mutation in the region of the rpoB gene was detected by a line probe assay in two of the isolates from these patients. We discuss several factors presumably associated with acquired drug resistance in HIV-infected patients, including exogenous reinfection, drug interactions, malabsorption of drugs, and the presence of a large organism burden.
Journal of Clinical Microbiology | 2007
Montserrat Garrigó; Lina Marcela Aragón; Fernando Alcaide; Sonia Borrell; Eugenia Cardeñosa; Juan José Galán; Julian González-Martín; Nuria Martín-Casabona; Carmen Moreno; Margarita Salvadó; Pere Coll
ABSTRACT In this multicenter study, the reliability of two nonradiometric, fully automated systems, the MB/BacT and BACTEC MGIT 960 systems, for testing the susceptibilities of 82 Mycobacterium tuberculosis strains to isoniazid, rifampin, ethambutol, and streptomycin was evaluated in comparison with the radiometric BACTEC 460TB system. The arbitration of discrepant results was done by the reanalysis of the strain, the determination of the MIC, and the molecular characterization of some resistance determinants. The overall level of agreement with BACTEC 460TB results was 96% with the MB/BacT test and 97.2% with the BACTEC MGIT 960 system. With both methods, the level of agreement with BACTEC 460TB results was 96.3% for isoniazid, 98.8% for rifampin, and 98.8% for ethambutol. The level of agreement for streptomycin was 90.2% with MB/BacT and 97.5% with BACTEC MGIT 960. Overall, there were 11 very major errors and 2 major errors with the MB/BacT method and 5 very major errors and 2 major errors with the BACTEC MGIT 960 system. In general, the MB/BacT and BACTEC MGIT 960 systems showed good performance for susceptibility testing with first-line antituberculosis drugs.
PLOS ONE | 2015
Marc Rubio; Francesca March; Montserrat Garrigó; Carmen Moreno; Montserrat Español; Pere Coll
Purpose Clarithromycin was considered the cornerstone for the treatment of Mycobacterium abscessus complex infections. Genetic resistance mechanisms have been described and many experts propose amikacin as an alternative. Nevertheless, clarithromycin has several advantages; therefore, it is necessary to identify the non-functional erm(41) allele to determine the most suitable treatment. The aims of this study were to characterize the molecular mechanisms of clarithromycin resistance in a collection of Mycobacterium abscessus complex isolates and to verify the relationship between these mechanisms and the antibiogram. Materials and Methods Clinical isolates of M. abscessus complex (n = 22) from 16 patients were identified using four housekeeping genes (rpoB, secA1, sodA and hsp65), and their genetic resistance was characterized by studying erm(41) and rrl genes. Nine strains were recovered from the clinical isolates and subjected to E-test and microdilution clarithromycin susceptibility tests, with readings at 3, 7 and 14 days. Results We classified 11/16 (68.8%) M. abscessus subsp. abscessus, 4/16 (25.0%) M. abscessus subsp. bolletii, and 1/16 (6.3%) M. abscessus subsp. massiliense. T28 erm(41) allele was observed in 8 Mycobacterium abscessus subps. abscessus and 3 Mycobacterium abscessus subsp. bolletii. One strain of M. abscessus subsp. bolletii had an erm(41) gene truncated and was susceptible to clarithromycin. No mutations were observed in rrl gene first isolates. In three patients, follow-up of initial rrl wild-type strains showed acquired resistance. Conclusions Most clinical isolates of M. abscessus complex had inducible resistance to clarithromycin and total absence of constitutive resistance. Our findings showed that the acquisition of resistance mutations in rrl gene was associated with functional and non-functional erm(41) gene. Caution is needed when using erm(41) sequencing alone to identify M. abscessus subspecies. This study reports an acquired mutation at position 2057 of rrl gene, conferring medium-low clarithromycin constitutive resistance.
Journal of Antimicrobial Chemotherapy | 2007
Lina Marcela Aragón; Montserrat Garrigó; Carmen Moreno; Montserrat Español; Pere Coll
Enfermedades Infecciosas Y Microbiologia Clinica | 2012
Óscar Esparcia; Montserrat Español; Montserrat Garrigó; Carmen Moreno; Michel Montemayor; Ferran Navarro; Pere Coll
Clinical Microbiology and Infection | 1999
Xavier Garriga; Pilar Cortés; Francesca March; Purificación Rodríguez; Montserrat Garrigó; Carmen Moreno; Elena Garcia; Pere Coll; Guillem Prats
Enfermedades Infecciosas Y Microbiologia Clinica | 1996
Rodríguez P; March F; Montserrat Garrigó; Carmen Moreno; Barrio J; Mercè Gurguí; Sambeat Ma; Pere Coll
Enfermedades Infecciosas Y Microbiologia Clinica | 1996
March F; Pere Coll; Costa R; Rodríguez P; Carmen Moreno; Montserrat Garrigó; G. Prats
Enfermedades Infecciosas Y Microbiologia Clinica | 1994
Carmen Moreno; Montserrat Garrigó; Sánchez F; Pere Coll
Enfermedades Infecciosas Y Microbiologia Clinica | 1995
Costa R; March F; Montserrat Garrigó; Carmen Moreno; Pere Coll